Halozyme Therapeutics (HALO) Q4 2023 earnings summary

Executive summary

• FY 2023 revenue rose 26% to $829.3M; Adjusted EBITDA was $426.2M and non-GAAP diluted EPS was $2.77.

• 2024 guidance was $915M–$985M revenue and $535M–$585M Adjusted EBITDA; a new $750M share repurchase program was authorized.

Financial highlights

• Q4 revenue increased 27% to $230.0M from $181.5M; royalty revenue rose 15% to $122.1M.

• Q4 operating income was $101.0M versus $74.5M, and net income was $85.4M versus $57.7M.

• FY revenue was $829.3M versus $660.1M, driven mainly by royalty growth, Antares acquisition contributions and higher bulk rHuPH20 sales.

• FY operating income was $337.6M versus $267.5M; net income was $281.6M versus $202.1M.

• FY royalties were $447.9M (+24%), product sales $300.9M (+57%), and collaboration revenue $80.5M (-26%).

Outlook and guidance

• 2024 revenue guidance is $915M–$985M, up 10%–19%; royalty guidance is $500M–$525M, up 12%–17%.

• 2024 Adjusted EBITDA guidance is $535M–$585M, up 26%–37%; non-GAAP diluted EPS guidance is $3.55–$3.90, up 28%–41%.

• 2024 product sales are projected at $285M–$300M; API sales are expected to decline following yield improvements and price reductions, with milestones and API sales weighted to H2.

• 2028 outlook: revenue $1.565B–$1.690B, royalties $1.000B–$1.050B, Adjusted EBITDA $1.125B–$1.250B and non-GAAP EPS $6.90–$7.50.

• 2023–2028 CAGRs are 14% for revenue, 18% for royalties, 9% for product sales, 23% for Adjusted EBITDA and 21% for non-GAAP EPS.